vyepti
h. lundbeck a/s - eptinezumab - migrän störningar - smärtstillande medel - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
evkeeza
ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipidmodifierande medel - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).
hemlibra
roche registration limited - emicizumab - hemofili a - hemostatika - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra kan användas i alla åldersgrupper.
raylumis
pfizer europe ma eeig - tanezumab - osteoarthritis; pain - smärtstillande medel - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.
feiba 50 e/ml pulver och vätska till infusionsvätska, lösning
baxalta innovations gmbh - protrombinkomplex, aktiverat - pulver och vätska till infusionsvätska, lösning - 50 e/ml - protrombinkomplex, aktiverat 50 e aktiv substans
feiba 25 e/ml pulver och vätska till infusionsvätska, lösning
baxalta innovations gmbh - protrombinkomplex, aktiverat - pulver och vätska till infusionsvätska, lösning - 25 e/ml - protrombinkomplex, aktiverat 25 e aktiv substans
roctavian
biomarin international limited - valoctocogene roxaparvovec - hemostatika - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).